ADMA Biologics is a U.S.-based biopharmaceutical company that manufactures, develops, and commercializes plasma-derived therapeutics, specifically specialty immune globulin products. The company operates an end-to-end supply chain, including plasma collection, fractionation, purification, and fill-finish capabilities, supported by a cGMP-compliant manufacturing facility. Its core business involves producing treatments for the prevention and management of infectious diseases in immune-compromised patients, with a focus on primary immunodeficiency disease. ADMA Biologics markets three FDA-approved products: ASCENIV, BIVIGAM, and Nabi-HB. The company sources plasma from its own vertically integrated collection centers and third-party partners. In addition to its proprietary product portfolio, ADMA Biologics offers contract development and manufacturing organization (CDMO) services, including aseptic filling, packaging, and GMP testing for external clients. The company utilizes a proprietary yield enhancement production process and a patented microneutralization assay to optimize manufacturing efficiency and measure antibody titer levels in donor samples.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage admabiologics.com
Sector Healthcare IR page ir.admabiologics.com
Tags
plasma-derived therapeutics, immune globulin, primary immunodeficiency, hepatitis b, biopharmaceutical manufacturing, cdmo services, plasma collection, aseptic filling, gmp testing, ASCENIV, BIVIGAM, Nabi-HB, ADMA BioCenters
Press page —

Metrics

Valuation  
Market cap $ 3.072B
Market cap (USD) $ 3.072B
P/E 17.90
PEG —
P/BV 7.00
P/S 5.92
P/OCF 21.82
P/FCF 23.11
Dividend yield —
Turnover / mcap —
Returns  
ROE 35.6%
ROI 26.7%
ROIC 28.0%
Profit margin 28.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 44.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 28
Quality score 41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009
Revenue 510.173M 426.454M 258.215M 154.08M 80.943M 42.22M 29.349M 16.985M 22.761M 10.661M 7.178M 5.916M 3.068M 1.118M 761.042K —
Net profit 146.93M 197.673M -28.239M -65.904M -71.648M -75.749M -48.279M -65.743M -43.759M -19.515M -17.97M -16.813M -15.527M -7.301M -5.903M —
Free cash flow 27.821M 110.446M 4.029M -73.419M -125.88M -114.73M -80.005M -64.774M -39.948M -18.342M -15.444M -17.028M -11.084M -7.023M -1.431M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009
Share price 18.24 17.15 4.52 3.88 1.41 1.95 4 2.39 3.21 5.12 8.08 11.17 7.3 — — —
Price performance 12m 0.06 2.79 0.16 1.75 -0.28 -0.51 0.67 -0.26 -0.37 -0.37 -0.28 0.53 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.02M 3.88M 1.39M 3.47M 13.2M 28.6M 15.5M 27.4M 50M 158M
↳ YoY growth +10.1% +281.1% -64.1% +149.2% +281.5% +115.9% -45.7% +76.9% +82.3% +216.9%
↳ 5y CAGR +150.8% +55.3% +70.3% +94.8% +31.9% +81.5% +70.5% +64.3%
Borrowings, current (USD) — — — — — — — — 0.00 2.81M
Borrowings, non-current (USD) — — — — — — — — 72.3M 69.3M
Lease liabilities (USD) — — — 229,073 365,682 8.05M 11.6M 10.8M 9.78M 7.74M
Cash and deposits (USD) 9.91M 43.1M 22.8M 26.8M 55.9M 51.1M 86.5M 51.4M 103M 87.6M
Intangible assets (USD) 0.00 4.85M 4M 3.16M 2.44M 1.73M 1.01M 499,000 460,000 632,000
Right-of-use assets (USD) — — — 1.25M 4.26M 7.26M 10.5M 9.64M 8.63M 6.65M
Net debt (borrowings + leases - cash) (USD) — — — — — — — — -21M -7.75M
Cash flow detail
Operating cash flow (USD) -18.3M -37.3M -62.7M -76.2M -102M -112M -59.5M 8.8M 119M 50.4M
Purchases of property, plant and equipment (USD) -73,410 -2.68M -2.1M -3.81M -12.7M -13.5M -13.9M -4.77M -8.23M -22.6M
Purchases of intangible assets (USD) — — — — — 0.00 0.00 -210,000 -349,000 -316,000
Change in receivables (cash effect) (USD) -93,559 -2.86M 2.49M -2.08M 9.77M -15.3M 13.1M -11.9M -22.6M -108M
Change in inventories (cash effect) (USD) -1.57M 589,318 -5.99M -34.7M 28.5M -43.2M -38.6M -9.63M 2.67M -36.2M
Change in payables (cash effect) (USD) 476,826 2.81M -20,480 3.27M 1.9M 1.36M 799,981 3.84M 4.15M 2.33M
Share buybacks (cash effect) (USD) — — — — — — — 0.00 0.00 -31.9M
Interest paid (cash effect) (USD) -1.53M -2.29M -4.4M -8.11M -8.11M -11.2M -13.9M -18.1M -10.7M -9.08M
Income taxes paid (cash effect) (USD) — — — — — — 0.00 0.00 -9.39M -19.7M
Share-based compensation (USD) 1.25M 1.56M 2.22M 2.65M 2.86M 3.49M 5.21M 6.19M 13.6M 20M
Operating cash flow before change in receivables (USD) -18.2M -34.4M -65.2M -74.1M -112M -97M -72.6M 20.7M 141M 159M
Free cash flow (OCF - PPE - intangibles) (USD) -18.3M -39.9M -64.8M -80M -115M -126M -73.4M 3.82M 110M 27.5M
Income detail
Research and development expense (USD) 7.69M 6.23M 3.93M 2.34M 5.91M 3.65M 3.61M 3.3M 1.81M 4.76M
↳ 5y CAGR +64.1% +12.4% -15.8% -24.4% -3.4% -13.9% -10.3% -3.4% -5.0% -4.2%
Reported Aug 11, 2017 Mar 29, 2018 Mar 13, 2019 Nov 5, 2020 Mar 25, 2021 Feb 28, 2024 Mar 18, 2025 Feb 25, 2026 Feb 25, 2026 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nov 4, 2026

PDF Version

3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year

3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year

3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year

3Q 2026 Adjusted Net Income(1) of $51.1 Million, Increasing 31% Year-over-Year

3Q 2026 GAAP Basic EPS of $0.22, Increasing 47% Year-over-Year

3Q 2026 Adjusted Basic EPS(2) of $0.23, Increasing 44% Year-over-Year

3Q 2026 Adjusted EBITDA(3) of $77.3 Million, Increasing 32% Year-over-Year

3Q 2026 Gross Margin of 71%, Expanding Approximately 1,450 Basis Points Year-over-Year

Expanding ASCENIV Real-World Health Outcomes Evidence Strengthens Commercial Differentiation

Robust Cash Generation, Operating Leverage and Share Repurchases Support Stockholder Value

Encouraging Regulatory Feedback Received from SG-001 Pre-IND Meeting Package

Reiterates FY2026 Revenue Guidance; Increases Adjusted Earnings Outlook

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its third quarter 2026 financial results and provided a business update.

“Our third quarter results demonstrate ADMA’s ability to translate accelerating ASCENIV demand into substantial earnings growth,” said Adam Grossman, President and Chief Executive Officer of ADMA. “ASCENIV revenue increased 31% year-over-year, driven by expanding physician adoption, new patient starts and growing end-user utilization. Favorable demand trends have continued into the fourth quarter, highlighting the durability of ASCENIV’s growth trajectory and significant remaining market opportunity. We are also encouraged by signs of stabilization in underlying BIVIGAM utilization, despite competitive pressures in the standard immune globulin market. Together with expanding margins and substantial per-share earnings growth, we believe these trends demonstrate the scalability and increasing profitability of our business.”

Mr. Grossman continued, “Our expanding real-world health outcomes evidence strengthens ASCENIV’s clinical value proposition among medically complex primary immunodeficiency patients and supports growing commercial adoption. With our yield-enhanced manufacturing capabilities, robust cash generation and disciplined capital allocation, we believe ADMA is well positioned to deliver sustained, profitable growth and long-term stockholder value creation. We are reiterating our full-year revenue outlook while increasing our minimum expectations for Adjusted Net Income and Adjusted EBITDA and continue to advance SG-001 as a potential additional long-term growth opportunity. We are also encouraged by the constructive FDA feedback recently received on our SG-001 pre-IND meeting package, which we believe represents an important milestone for the program. Notably, we received constructive feedback from the FDA regarding the proposed clinical development strategy, including key elements of the planned clinical study. Based on the FDA’s feedback, we intend to incorporate the recommendations into the final clinical protocol and advance preparations for an IND submission. The FDA also indicated that our proposed assay would be acceptable for product testing, subject to appropriate validation. We believe this feedback supports a potentially efficient development pathway that leverages ADMA’s established manufacturing capabilities and clinical development experience as we advance SG-001 toward clinical trials.”

Reiterated FY2026 Revenue Guidance and Increased Adjusted Earnings Outlook

  • FY2026 total revenue expected to be at least $530 million

  • FY2026 Adjusted Net Income expected to be at least $180 million

  • FY2026 Adjusted EBITDA expected to be at least $275 million

ADMA’s FY2026 outlook reflects continued ASCENIV commercial momentum and conservative assumptions for competitive conditions in the U.S. standard immune globulin market. Favorable ASCENIV utilization trends have continued into the fourth quarter, while underlying BIVIGAM utilization has shown encouraging signs of stabilization.

Third Quarter Commercial and Operational Highlights

  • ASCENIV Growth Accelerated and Momentum Extended Into the Fourth Quarter. ASCENIV revenue in the third quarter reached $124.7 million, increasing 31% year-over-year and 21% sequentially, driven by expanding physician adoption, new patient starts and growing end-user utilization. Favorable pull-through trends continued into the fourth quarter, supporting confidence in the product’s growth trajectory.

  • BIVIGAM Utilization Showed Encouraging Signs of Stabilization. Third quarter BIVIGAM revenue was $15.4 million, compared with $19.4 million in the second quarter, reflecting continued competitive pricing and channel inventory pressures in the standard immunoglobulin (IG) market. Despite the sequential revenue decline, underlying end-user utilization showed encouraging signs of stabilization entering the fourth quarter. ADMA remains focused on disciplined commercial participation rather than matching aggressive competitor rebating and discounting.

  • ASCENIV Real-World Health Outcomes Evidence Strengthened Differentiation. ADMA plans to present an analysis of 127 medically complex primary immunodeficiency (“PI”) patients treated with ASCENIV, most of whom had previously received other immune globulin therapies, in mid-November at the American College of Allergy, Asthma and Immunology (ACAAI) annual conference. The analysis identified statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, oral antibiotic use and corticosteroid use following ASCENIV initiation, supporting its positioning among later-line, refractory and medically complex PI patients.

  • The study included patients with PI and respiratory comorbidities, substantial antimicrobial or corticosteroid use, or recurrent infection-related healthcare utilization.

  • The analysis compared outcomes during the 12 months before ASCENIV initiation with the 12 months after initiation.

  • Third-Quarter Performance Demonstrated Significant Operating Leverage. Total revenue increased 13% sequentially to $141.1 million, while Adjusted EBITDA grew 25% quarter-over-quarter to $77.3 million. Gross margin reached 71%, compared with 69% sequentially and 56% in the third quarter of 2025, reflecting favorable ASCENIV mix and benefits from yield-enhanced manufacturing.

  • Strong Cash Generation and Disciplined Capital Allocation Support Stockholder Value. ADMA continued repurchasing shares of its common stock while investing in commercial growth, manufacturing efficiencies and SG-001 development. During the third quarter, ADMA repurchased 2.7 million shares of common stock under its previously authorized share repurchase program. Year-to-date total stock repurchases through September 30, 2026 were 16.5 million shares, amounting to 6.3% of the Company’s common stock outstanding as of December 31, 2025. The Company continues to act opportunistically in repurchasing shares and is on track to complete its previously stated $200 million or more 2026 share repurchase target.

  • SG-001 Development Progressed Through Capital-Efficient Innovation. ADMA advanced preclinical, assay development and manufacturing-readiness activities for SG-001, its investigational pneumococcal hyperimmune globulin candidate. The Company used its proprietary ADMAlytics screening and predictive analytics platform, incorporating computational modeling and artificial intelligence, to forecast final titer values from limited experimental data, with the aim of improving analytical efficiency and reducing laboratory testing requirements in humanized mouse models. ADMA expects to leverage its existing manufacturing infrastructure as development advances. ADMA believes that should SG-001 receive FDA approval, this could represent a $300-500 million annual revenue opportunity for the Company.

  • The Company recently received constructive FDA feedback on its SG-001 pre-IND meeting package regarding the proposed clinical development strategy, including key elements of the planned clinical study. Based on the FDA’s feedback, the Company intends to incorporate the recommendations into the final clinical protocol and advance preparations for an IND submission. The FDA also indicated that ADMA’s proposed assay would be acceptable for product testing, subject to appropriate validation.

  • Immunocompromised patients face elevated risks of severe pneumococcal disease and may receive limited protection from vaccination, underscoring the need for targeted preventive approaches. ADMA believes its preclinical findings and recently received FDA feedback on its pre-IND meeting package support continued development of SG-001.

Third Quarter 2026 Financial Results:

Total revenue for the quarter ended September 30, 2026 was $141.1 million, compared with $134.2 million for the quarter ended September 30, 2025 and $124.4 million in the second quarter of 2026, representing growth of 5% year-over-year and 13% sequentially. ASCENIV revenue was $124.7 million, increasing 31% year-over-year and 21% sequentially. BIVIGAM revenue was $15.4 million, compared with $23.8 million in the prior-year quarter and $19.4 million in the second quarter of 2026.

Gross profit for the quarter ended September 30, 2026 was $99.9 million, compared with $75.6 million in the prior-year period and $86.3 million in the second quarter of 2026. Gross margin expanded to 71%, compared with 56% in the prior-year quarter and 69% in the second quarter. Margin expansion reflected favorable ASCENIV product mix and the continued benefits of the Company’s yield-enhanced manufacturing process.

Research and development expenses for the quarter ended September 30, 2026 were approximately $4.5 million, compared with $1.5 million in the prior-year period and $6.0 million in the second quarter of 2026, reflecting continued SG-001 development investment with lower sequential plasma collection activity.

Selling, general and administrative expenses for the quarter ended September 30, 2026 were approximately $26.6 million, compared with $21.7 million in the prior-year period and $26.7 million in the second quarter of 2026. The year-over-year increase primarily reflected additional personnel and professional fees, as well as legal fees associated with ongoing litigation related matters, while expense levels remained relatively stable sequentially.

GAAP net income for the quarter ended September 30, 2026 was $49.9 million, compared with $36.4 million in the prior-year period and $37.8 million in the second quarter of 2026, representing growth of approximately 37% year-over-year and 32% sequentially.

GAAP basic EPS for the quarter ended September 30, 2026 was $0.22, compared with $0.15 in the prior-year period and $0.17 in the second quarter of 2026 representing growth of approximately 47% year-over-year and 29% sequentially.

Adjusted Net Income for the quarter ended September 30, 2026 was $51.1 million, compared with $38.9 million in the prior-year period and $39.0 million in the second quarter of 2026, increasing approximately 31% year-over-year and sequentially.

Adjusted Basic EPS for the quarter ended September 30, 2026 was $0.23, compared with $0.16 in the prior-year period and $0.17 in the second quarter of 2026, representing growth of approximately 44% year-over-year.

Adjusted EBITDA for the quarter ended September 30, 2026 was $77.3 million, compared with $58.7 million in the prior-year period and $61.8 million in the second quarter of 2026, representing growth of 32% year-over-year and 25% sequentially.

Nine Months Ended September 30, 2026 Financial Results:

Total revenue for the nine months ended September 30, 2026 was $380.0 million, compared with $371.0 million in the prior-year period, representing growth of 2%. ASCENIV revenue was $325.1 million, increasing 27% year-over-year; BIVIGAM revenue was $50.2 million, compared with $95.0 million in the prior-year period.

Gross profit for the nine months ended September 30, 2026 was $266.9 million, compared with $203.9 million in the prior-year period. Gross margin expanded to 70%, compared with 55% in the prior-year period, reflecting a favorable shift toward ASCENIV and yield-enhancement benefits.

Research and development expenses for the nine months ended September 30, 2026 were approximately $13.1 million, compared with $3.4 million in the prior-year period, primarily reflecting SG-001 development activities.

Selling, general and administrative expenses for the nine months ended September 30, 2026 were approximately $80.0 million, compared with $68.1 million in the prior-year period, primarily reflecting an increase in personnel costs and professional fees, as well as legal fees related to ongoing litigation and related matters.

GAAP net income for the nine months ended September 30, 2026 was $133.0 million, compared with $97.6 million in the prior-year period.

GAAP basic EPS for the nine months ended September 30, 2026 was $0.58, compared with $0.41 in the prior-year period.

Adjusted Net Income for the nine months ended September 30, 2026 was $130.7 million, compared with $108.2 million in the prior-year period, representing growth of 21%.

Adjusted Basic EPS for the nine months ended September 30, 2026 was $0.56, compared with $0.45 in the prior-year period, representing growth of 24%.

Adjusted EBITDA for the nine months ended September 30, 2026 was $198.8 million, compared with $157.4 million in the prior-year period, representing growth of 26%.

Conference Call Information

To seamlessly access the conference call on November 4, 2026 at 4:30 p.m. ET, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available, located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.

About ASCENIV™

ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). ASCENIV was approved by the United States Food and Drug Administration (FDA) in April 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), also known as primary immune deficiency disease (PIDD), in adults and pediatric patients (2 years of age and older). ASCENIV is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and respiratory syncytial virus (RSV) plasma obtained from donors tested using the Company’s proprietary microneutralization assay. ASCENIV contains naturally occurring polyclonal antibodies, which are proteins that are used by the body’s immune system to neutralize microbes such as bacteria and viruses that safeguard against infection and disease. ASCENIV is protected by numerous issued patents in the United States and internationally and a wide range of patent applications worldwide. Certain data and other information about ASCENIV can be found by visiting www.asceniv.com. Information about ADMA and its products can be found on the Company’s website at www.admabiologics.com.

Additional Important Safety Information About ASCENIV™

| WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE |

| |

| Thrombosis may occur with immune globulin intravenous (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Such events require immediate medical intervention, if not recognized or managed appropriately, may result in persistent or significant disability or lead to fatal outcome. For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. |

ASCENIV™ Contraindications:

History of anaphylactic or severe systemic reactions to human immunoglobulin.

IgA deficient patients with antibodies to IgA and a history of hypersensitivity.

ASCENIV™ Warnings and Precautions:

IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have medications such as epinephrine available to treat any acute severe hypersensitivity reactions. [4, 5.1]

Thrombotic events have occurred in patients receiving IGIV treatments. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for patients at risk of hyperviscosity. [5.2, 5.4]

In patients at risk of developing acute renal failure, monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output. [5.3, 5.9]

Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV treatment. [5.4]

Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. [5.5]

Hemolytic anemia can develop subsequent to IGIV treatment. Monitor patients for hemolysis and hemolytic anemia. [5.6]

Monitor patients for pulmonary adverse reactions (Transfusion-related acute lung injury [TRALI]). If transfusion-related acute lung injury is suspected, test the product and patient for antineutrophil antibodies. [5.7]

Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. [5.8]

ASCENIV™ Adverse Reactions:

The most common adverse reactions to ASCENIV (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea.

To report SUSPECTED ADVERSE REACTIONS, contact ADMA Biologics at (800) 458-4244 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumoniae. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products and product candidates. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons.

ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

Use of Non-GAAP Financial Measures

This press release includes certain non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The Company believes Adjusted EBITDA, Adjusted Net Income, and Adjusted Basic EPS are useful to investors in evaluating the Company’s financial performance. The Company uses Adjusted EBITDA, Adjusted Net Income and Adjusted Basic EPS as key performance measures because it believes that they facilitate operating performance comparisons from period to period that exclude potential differences driven by the impact of variations of non-cash items such as depreciation and amortization, as well as, in the case of Adjusted EBITDA, stock-based compensation or certain non-recurring items, in the case of Adjusted Net Income, certain non-recurring items, and in the case of Adjusted Basic EPS, the impact of the adjustments reflected in Adjusted Net Income on basic weighted average outstanding shares. The Company believes that investors should have access to the same set of tools used by its management and Board of Directors to assess its operating performance. Adjusted EBITDA, Adjusted Net Income and Adjusted Basic EPS should not be considered as measures of financial performance under GAAP, and the items excluded from Adjusted EBITDA, Adjusted Net Income and Adjusted Basic EPS are significant components in understanding and assessing the Company’s financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income, cash flows from operations, or any other performance measures derived in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Please refer to the tables below for the reconciliation of GAAP measures to these non-GAAP measures for applicable periods.

The Company has not provided a reconciliation of its forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure because certain items that are excluded from such non-GAAP financial measures cannot be reasonably predicted or estimated without unreasonable effort. These items may include, but are not limited to, costs associated with potential business development, licensing, collaboration, acquisition, divestiture or other strategic transactions; unusual legal, litigation, regulatory, settlement and related professional fees, expenses and other organizational optimization costs; and other unusual, non-recurring, infrequent or non-cash items that may arise during the applicable period.

The timing, occurrence, and magnitude of these items are inherently uncertain and depend on a variety of factors that are outside of the Company's control or cannot be reasonably predicted at this time. Accordingly, management is unable to estimate these amounts with reasonable certainty or determine the probable significance of such items to the corresponding GAAP financial measure without unreasonable effort. These items could have a material impact on the Company's GAAP results for the applicable reporting period.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “position us,” “positioned,” “support,” “should,” “could,” “would,” “may,” “potential,” “view,” “opportunity” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about: the Company’s total revenue, Adjusted Net Income, Adjusted EBITDA, earnings and earnings potential, profitability, scalability, financial guidance in future periods and related assumptions; the Company’s ability to generate stockholder value and related drivers; the current U.S. immune globulin market, including competitive pressures and conditions; ASCENIV revenue growth and potential, value proposition, market opportunity, growth trajectory, appropriate market, adoption, demand and utilization; our ability and plans to complete our 2026 share repurchase target; real-world health outcomes evidence (including, but not limited to, certain patient analyses expected to be presented) and the beneficial impact for ASCENIV’s clinical value and commercial adoption; BIVIGAM potential with signs of stabilization in underlying BIVIGAM utilization; and SG-001, its data, regulatory filings and submissions, revenue potential, growth opportunity and clinical development plans and timeline, the incorporation of FDA feedback into the final clinical protocol, preparations for an IND submission, the potential efficiency of the development pathway, as well as our ability to leverage our existing manufacturing infrastructure in the development of SG-001. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

(1) Adjusted Net Income is a non-GAAP financial measure. The most directly comparable financial measure calculated and presented in accordance with GAAP is Net Income. For a reconciliation of Adjusted Net Income to Net Income, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.

(2) Adjusted Basic EPS is a non-GAAP financial measure. The most directly comparable financial measure calculated and presented in accordance with GAAP is Basic EPS. For a reconciliation of Adjusted Basic EPS to Basic EPS, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.

(3) Adjusted EBITDA is a non-GAAP financial measure. The most directly comparable financial measure calculated and presented in accordance with GAAP is Net Income. For a reconciliation of Adjusted EBITDA to Net Income, see the reconciliation included in the financial tables.

INVESTOR RELATIONS CONTACT: Argot Partners | 212-600-1902 | [email protected]

MEDIA CONTACT: Longacre Square Partners | [email protected]

| ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS |

| | | | | |

| | September 30, | | December 31, | |

| | 2026 | | 2025 | |

| | (in thousands, except share and per share data) | |

| | Unaudited | | | |

| ASSETS | | | | |

| Current assets: | | | | |

| Cash and cash equivalents | $ | 124,555 | | | $ | 87,630 | | |

| Accounts receivable, net | | 169,223 | | | | 158,429 | | |

| Inventories, net | | 266,115 | | | | 206,465 | | |

| Prepaid expenses and other current assets | | 15,969 | | | | 7,458 | | |

| Assets held for sale | | - | | | | 6,530 | | |

| Total current assets | | 575,862 | | | | 466,512 | | |

| Property and equipment, net | | 66,761 | | | | 65,057 | | |

| Intangible assets, net | | 581 | | | | 632 | | |

| Goodwill | | 3,530 | | | | 3,530 | | |

| Deferred tax assets, net | | 70,693 | | | | 73,261 | | |

| Right-of-use assets | | 5,881 | | | | 6,650 | | |

| Deposits and other assets | | 9,177 | | | | 8,600 | | |

| TOTAL ASSETS | $ | 732,485 | | | $ | 624,242 | | |

| | | | | |

| LIABILITIES AND STOCKHOLDERS' EQUITY | | | | |

| Current liabilities: | | | | |

| Accounts payable | $ | 35,660 | | | $ | 22,519 | | |

| Accrued expenses and other current liabilities | | 54,217 | | | | 40,466 | | |

| Current portion of long-term debt | | 4,219 | | | | 2,813 | | |

| Current portion of lease obligations | | 1,180 | | | | 1,096 | | |

| Liabilities held for sale | | - | | | | 2,647 | | |

| Total current liabilities | | 95,276 | | | | 69,541 | | |

| Long-term debt | | 191,638 | | | | 69,330 | | |

| Deferred revenue, net of current portion | | 1,297 | | | | 1,405 | | |

| Lease obligations, net of current portion | | 5,767 | | | | 6,646 | | |

| TOTAL LIABILITIES | $ | 293,978 | | | $ | 146,922 | | |

| | | | | |

| COMMITMENTS AND CONTINGENCIES | | | | |

| | | | | |

| STOCKHOLDERS' EQUITY | | | | |

| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, | | | | |

| no shares issued and outstanding | | - | | | | - | | |

| Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, | | | | |

| September 30, 2026: 241,251,158 issued and 222,793,831 outstanding; December 31, 2025: 239,793,566 issued and 237,874,496 outstanding | | 24 | | | | 24 | | |

| Treasury stock, at cost, 18,457,327 and 1,919,070 shares as of September 30, 2026 | | | | |

| and December 31, 2025, respectively | | (213,736 | ) | | | (32,090 | ) | |

| Additional paid-in capital | | 680,838 | | | | 671,039 | | |

| Accumulated deficit | | (28,619 | ) | | | (161,653 | ) | |

| TOTAL STOCKHOLDERS' EQUITY | | 438,507 | | | | 477,320 | | |

| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 732,485 | | | $ | 624,242 | | |

| | | | | |

| ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS NON-GAAP RECONCILIATION | |

| | | | | | | | | | |

| | | Three Months Ended September 30, | | Nine Months Ended September 30, | |

| | | 2026 | | 2025 | | 2026 | | 2025 | |

| | | (in thousands, except share and per share data) | |

| | | Unaudited | |

| | | | | | | | | | |

| REVENUES | | $ | 141,102 | | | $ | 134,224 | | | $ | 379,990 | | | $ | 371,010 | | |

| Cost of product revenue | | | 41,185 | | | | 58,598 | | | | 113,046 | | | | 167,061 | | |

| Gross profit | | | 99,917 | | | | 75,626 | | | | 266,944 | | | | 203,949 | | |

| | | | | | | | | | |

| OPERATING EXPENSES: | | | | | | | | | |

| Research and development | | | 4,490 | | | | 1,528 | | | | 13,101 | | | | 3,386 | | |

| Plasma center operating expenses | | | 1,055 | | | | 1,272 | | | | 3,143 | | | | 3,710 | | |

| Amortization of intangible assets | | | 60 | | | | 38 | | | | 170 | | | | 93 | | |

| Gain on sale of plasma centers | | | - | | | | - | | | | (7,980 | ) | | | - | | |

| Selling, general and administrative | | | 26,555 | | | | 21,776 | | | | 80,034 | | | | 68,068 | | |

| Total operating expenses | | | 32,160 | | | | 24,614 | | | | 88,468 | | | | 75,257 | | |

| | | | | | | | | | |

| INCOME FROM OPERATIONS | | | 67,757 | | | | 51,012 | | | | 178,476 | | | | 128,692 | | |

| | | | | | | | | | |

| OTHER INCOME (EXPENSE): | | | | | | | | | |

| Interest and other income | | | 1,298 | | | | 376 | | | | 3,629 | | | | 1,384 | | |

| Interest expense | | | (3,432 | ) | | | (1,675 | ) | | | (8,956 | ) | | | (5,484 | ) | |

| Loss on extinguishment of debt | | | - | | | | (2,177 | ) | | | - | | | | (3,336 | ) | |

| Other expense | | | (19 | ) | | | (21 | ) | | | (180 | ) | | | (195 | ) | |

| Other income (expense), net | | | (2,153 | ) | | | (3,497 | ) | | | (5,507 | ) | | | (7,631 | ) | |

| | | | | | | | | | |

| INCOME BEFORE INCOME TAXES | | | 65,604 | | | | 47,515 | | | | 172,969 | | | | 121,061 | | |

| | | | | | | | | | |

| Provision for income taxes | - | | 15,720 | | | | 11,087 | | | | 39,935 | | | | 23,510 | | |

| | | | | | | | | | |

| NET INCOME | | $ | 49,884 | | | $ | 36,428 | | | $ | 133,034 | | | $ | 97,551 | | |

| | | | | | | | | | |

| BASIC EARNINGS PER COMMON SHARE | | $ | 0.22 | | | $ | 0.15 | | | $ | 0.58 | | | $ | 0.41 | | |

| DILUTED EARNINGS PER COMMON SHARE | | $ | 0.22 | | | $ | 0.15 | | | $ | 0.57 | | | $ | 0.40 | | |

| | | | | | | | | | |

| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | | | | | | | | | |

| Basic | | | 223,695,193 | | | | 238,602,978 | | | | 229,291,798 | | | | 238,408,042 | | |

| Diluted | | | 225,820,678 | | | | 244,664,263 | | | | 232,105,293 | | | | 245,491,334 | | |

| | | | | | | | | | |

| RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA(3) |

| | | | | |

| | | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | 2025 | | 2026 | | 2025 |

| | | (in thousands) |

| | | Unaudited |

| Net income | | $ | 49,884 | | $ | 36,428 | | $ | 133,034 | | | $ | 97,551 |

| Depreciation | | | 1,729 | | | 1,987 | | | 5,239 | | | | 5,957 |

| Amortization | | | 60 | | | 38 | | | 170 | | | | 93 |

| Income taxes | | | 15,720 | | | 11,087 | | | 39,935 | | | | 23,510 |

| Interest expense, net | | 2,134 | | | 1,675 | | | 5,303 | | | | 5,484 |

| EBITDA | | | 69,527 | | | 51,215 | | | 183,681 | | | | 132,595 |

| Stock-based compensation | | 6,203 | | | 5,047 | | | 18,666 | | | | 14,634 |

| Voluntary Withdrawal and product replacements | | - | | | - | | | - | | | | 4,001 |

| Yield enhancement | | 181 | | | 301 | | | 1,022 | | | | 1,696 |

| Gain on sale of plasma centers | | - | | | - | | | (7,980 | ) | | | - |

| Loss on extinguishment of debt | | - | | | 2,177 | | | - | | | | 3,336 |

| Non-recurring professional fees | | 1,368 | | | - | | | 3,388 | | | | 1,182 |

| Adjusted EBITDA | $ | 77,279 | | $ | 58,740 | | $ | 198,777 | | | $ | 157,444 |

| | | | | | | | | |

| NON-GAAP RECONCILIATION RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NET INCOME(1) | |

| | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |

| | 2026 | | 2025 | | 2026 | | 2025 | |

| | (in thousands) | |

| | Unaudited | |

| Net income | $ | 49,884 | | $ | 36,428 | | $ | 133,034 | | | $ | 97,551 | |

| Stock-based compensation modifications | | - | | | - | | | 609 | | | | 474 | |

| Customer credits related to the Voluntary Withdrawal | | - | | | - | | | - | | | | 4,001 | |

| Loss on extinguishment of debt | | - | | | 2,177 | | | - | | | | 3,336 | |

| Yield Enhancement | | 138 | | | 301 | | | 788 | | | | 1,696 | |

| Gain on sale of plasma centers | | - | | | - | | | (6,332 | ) | | | - | |

| Non-recurring professional fees | | 1,040 | | | - | | | 2,599 | | | | 1,182 | |

| Adjusted net income**(a)** | $ | 51,062 | | $ | 38,906 | | $ | 130,698 | | | $ | 108,240 | |

| | | | | | | | | |

| (a) Add-backs reflected during the three and nine months ended September 30, 2025 exclude estimated tax effect of $0.6 million and $2.1 million, respectively. Add-backs reflected during the three months and nine months ended September 30, 2026 were tax affected using the respective effective tax rates. | |

| | |

| NON-GAAP RECONCILIATION RECONCILIATION OF BASIC EARNINGS PER SHARE TO ADJUSTED EARNINGS PER SHARE(2) | |

| | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |

| | 2026 | | 2025 | | 2026 | | 2025 | |

| | (in thousands) | |

| | Unaudited | |

| Net income | $ | 49,884 | | $ | 36,428 | | $ | 133,034 | | | $ | 97,551 | |

| Stock-based compensation modifications | | - | | | - | | | 609 | | | | 474 | |

| Customer credits related to the Voluntary Withdrawal | | - | | | - | | | - | | | | 4,001 | |

| Loss on extinguishment of debt | | - | | | 2,177 | | | - | | | | 3,336 | |

| Yield Enhancement | | 138 | | | 301 | | | 788 | | | | 1,696 | |

| Gain on sale of plasma centers | | - | | | - | | | (6,332 | ) | | | - | |

| Non-recurring professional fees | | 1,040 | | | - | | | 2,599 | | | | 1,182 | |

| Adjusted net income**(a)** | $ | 51,062 | | $ | 38,906 | | $ | 130,698 | | | $ | 108,240 | |

| | | | | | | | | |

| Basic earnings per common share | $ | 0.22 | | $ | 0.15 | | $ | 0.58 | | | $ | 0.41 | |

| Stock-based compensation modifications | | - | | | - | | | - | | | | - | |

| Customer credits related to the Voluntary Withdrawal | | - | | | - | | | - | | | | 0.02 | |

| Loss on extinguishment of debt | | - | | | 0.01 | | | - | | | | 0.01 | |

| Yield Enhancement | | - | | | - | | | - | | | | 0.01 | |

| Gain on sale of plasma centers | | - | | | - | | | (0.03 | ) | | | - | |

| Non-recurring professional fees | | 0.01 | | | - | | | 0.01 | | | | - | |

| Adjusted basic EPS**(b)** | $ | 0.23 | | $ | 0.16 | | $ | 0.56 | | | $ | 0.45 | |

| | | | | | | | | |

| (a) Add-backs reflected during the three and nine months ended September 30, 2025 exclude estimated tax effect of $0.6 million and $2.1 million, respectively. Add-backs reflected during the three months and nine months ended September 30, 2026 were tax affected using the respective effective tax rates. | |

| (b) Adjusted basic EPS is measured using basic weighted-average shares outstanding. | |

| | | | | | | | | |

| PRODUCT-LEVEL TOTAL REVENUE |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | Increase/ (Decrease) | | Increase/ (Decrease) % | | 2026 | | 2025 | | Increase/ (Decrease) | | Increase/ (Decrease) % |

| (in thousands) | Unaudited |

| ASCENIV | $ | 124,742 | | $ | 95,410 | | $ | 29,332 | | | 30.7 | % | | $ | 325,149 | | $ | 255,063 | | $ | 70,086 | | | 27.5 | % |

| BIVIGAM | | 15,390 | | | 23,763 | | | (8,373 | ) | | (35.2 | %) | | | 50,231 | | | 94,984 | | | (44,753 | ) | | (47.1 | %) |

| Intermediates and other products (1) | | 909 | | | 15,015 | | | (14,106 | ) | | (93.9 | %) | | | 3,039 | | | 19,806 | | | (16,767 | ) | | (84.7 | %) |

| ADMA BioManufacturing | | 141,041 | | | 134,188 | | | 6,853 | | | 5.1 | % | | | 378,419 | | | 369,853 | | | 8,567 | | | 2.3 | % |

| | | | | | | | | | | | | | | | |

| Plasma Collection Centers | | 25 | | | - | | | 25 | | | 100.0 | % | | | 1,464 | | | 1,050 | | | 414 | | | 39.4 | % |

| License revenue | | 36 | | | 36 | | | - | | | 0.0 | % | | | 107 | | | 107 | | | - | | | 0.0 | % |

| Total Revenues | $ | 141,102 | | $ | 134,224 | | $ | 6,878 | | | 5.1 | % | | $ | 379,990 | | $ | 371,010 | | $ | 8,981 | | | 2.4 | % |

| | | | | | | | | | | | | | | | |

| (1) Due to Nabi-HB historically representing less than 10% of the Company's revenue within the ADMA BioManufacturing segment, it has been included under intermediates and other products. |

| |

| ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF CASH FLOWS | |

| | |

| | | | | | Nine Months Ended September 30, | |

| | | | | | 2026 | | 2025 | |

| (In thousands) | | | | | |

| CASH FLOWS FROM OPERATING ACTIVITIES: | | | | |

| | Net income | | | 133,034 | | | | 97,551 | | |

| | Adjustments to reconcile net income to net | | | | | |

| | | cash provided by operating activities: | | | | | |

| | | | Depreciation and amortization | | | 5,409 | | | | 6,050 | | |

| | | | Gain on sale of plasma centers | | | (7,980 | ) | | | - | | |

| | | | Loss on disposal of fixed assets | | | 42 | | | | - | | |

| | | | Deferred income tax provision | | | 2,569 | | | | 9,848 | | |

| | | | Stock-based compensation | | | 18,667 | | | | 14,634 | | |

| | | | Amortization of debt discount | | | 589 | | | | 520 | | |

| | | | Loss on extinguishment of debt | | | - | | | | 3,336 | | |

| | | | Amortization of license revenue | | | (107 | ) | | | (107 | ) | |

| | Changes in operating assets and liabilities: | | | | | |

| | | | Accounts receivable, net | | | (10,794 | ) | | | (87,674 | ) | |

| | | | Inventories | | | (59,650 | ) | | | (26,432 | ) | |

| | | | Prepaid expenses and other current assets | | | (2,514 | ) | | | (978 | ) | |

| | | | Deposits and other assets | | | 192 | | | | (261 | ) | |

| | | | Accounts payable | | | 12,958 | | | | 4,533 | | |

| | | | Accrued expenses | | | 13,675 | | | | (5,427 | ) | |

| | | | Other current and non-current liabilities | | | (934 | ) | | | (836 | ) | |

| | | | Net cash provided by operating activities | | | 105,156 | | | | 14,757 | | |

| | | | | | | | | |

| CASH FLOWS FROM INVESTING ACTIVITIES: | | | | |

| | | | Purchase of property and equipment | | | (6,801 | ) | | | (21,491 | ) | |

| | | | Acquisition of intangible assets | | | (119 | ) | | | (124 | ) | |

| | | | Proceeds on the sales of assets held for sale | | | 5,000 | | | | - | | |

| | | | Net cash used in investing activities | | | (1,920 | ) | | | (21,615 | ) | |

| | | | | | | | | |

| CASH FLOWS FROM FINANCING ACTIVITIES: | | | | |

| | | | Ares term loan payments | | | - | | | | (32,500 | ) | |

| | | | Ares revolving facility payments | | | - | | | | (72,500 | ) | |

| | | | Ares revolving facility proceeds | | | - | | | | 30,000 | | |

| | | | JPM term loan payments | | | (1,875 | ) | | | (469 | ) | |

| | | | JPM revolving facility proceeds | | | 125,000 | | | | 75,000 | | |

| | | | Prepayment penalties on repayment of debt | | | - | | | | (1,031 | ) | |

| | | | Taxes paid on vested restricted stock units | | | (9,769 | ) | | | (9,383 | ) | |

| | | | Debt issuance costs | | | - | | | | (2,224 | ) | |

| | | | Net proceeds from the exercise of stock options | | 633 | | | | 2,554 | | |

| | | | Payment of end of term fee | | | - | | | | (1,313 | ) | |

| | | | Acquisition of treasury stock | | | (180,300 | ) | | | (23,038 | ) | |

| | | | Net cash used in financing activities | | | (66,311 | ) | | | (34,904 | ) | |

| | | | | | | | | |

| Net increase (decrease) in cash and cash equivalents | | 36,925 | | | | (41,762 | ) | |

| Cash and cash equivalents - beginning of period | | | 87,630 | | | | 103,147 | | |

| Cash and cash equivalents - end of period | | $ | 124,555 | | | $ | 61,385 | | |

Oct 28, 2026

PDF Version

Conference Call Scheduled for November 4, 2026, at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report third quarter 2026 financial results on November 4, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.

To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here**.**An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products and product candidates. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons.

ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

INVESTOR RELATIONS CONTACT:

Argot Partners | 212-600-1902 | [email protected]

MEDIA CONTACT:

Longacre Square Partners | [email protected]

Oct 15, 2026

PDF Version

Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield

No Thromboembolic Events Were Reported for ADMA IVIG Products Manufactured Using the Optimized Process During the Postmarketing Surveillance Period Evaluated

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine detailing new data from the Company’s optimized, proprietary intravenous immune globulin (“IVIG”) manufacturing process.

The article, titled “Further Optimization of an ADMA Biologics’ Proprietary Manufacturing Process to Ensure Removal of Impurities Associated With Thrombosis Risk in IVIG Products,” reports the results of analytical testing performed on three commercial-scale lots of ADMA’s IVIG products manufactured using its U.S. Food and Drug Administration (FDA)-licensed further optimized process.

Thromboembolic events (“TEEs”) are rare but serious adverse events associated with immune globulin therapy. Patient-specific risk factors and certain product-related impurities can contribute to the potential risk of these events. ADMA further optimized its proprietary manufacturing process to enhance the removal of procoagulant and other impurities while maintaining immunoglobulin purity, quality and structural integrity.

Key findings reported in the publication include:

  • All evaluated procoagulant and product-related impurities, including Factor XIa, IgA, IgM, cholesterol and prekallikrein activator, were measured at or below applicable quantification limits across the three lots tested.

  • Two of the three evaluated lots had Factor XIa levels below the limit of quantification. Factor XIa has been associated with thrombotic risk in immune globulin products.

  • The three lots demonstrated an average non-activated partial thromboplastin time (“NAPTT”) exceeding 250 seconds, indicating very low procoagulant activity. NAPTT results greater than 200 seconds have been associated with a reduced incidence of TEEs.

  • Chromatographic testing detected no immunoglobulin aggregates or fragments.

  • The optimized process increased immunoglobulin yield while maintaining product quality and IgG integrity.

  • ADMA’s postmarketing pharmacovigilance surveillance and the FDA Adverse Event Reporting System received no reports of TEEs associated with ADMA IVIG products manufactured using the further optimized process from July 1, 2025 through July 31, 2026.

“Patients with primary humoral immunodeficiency may require lifelong immune globulin therapy, making product quality and continued manufacturing innovation critically important,” said Adam Grossman, President and Chief Executive Officer of ADMA. “The findings reported in this peer-reviewed publication demonstrate the capabilities of ADMA’s proprietary manufacturing platform to remove impurities associated with thrombotic risk while maintaining immunoglobulin quality and increasing IgG recovery. We believe these results further support the differentiated quality profile of our IVIG portfolio and reinforce ADMA’s commitment to advancing manufacturing science for the benefit of immune-compromised patients.”

“Thromboembolic events are uncommon but clinically important complications of immunoglobulin therapy, making the control of procoagulant impurities an important component of IVIG manufacturing. The very low procoagulant activity observed in this analysis, together with effective removal of Factor XIa and other impurities and the absence of reported thromboembolic events during the post-marketing observation period, provides reassuring evidence regarding the quality and safety profile of IVIG produced using ADMA’s further optimized manufacturing process,” said Dr. Maeve O’Connor, Chief Medical Officer, Consortium of Independent Immunology Clinics (CIIC) & CEO and Medical Director, Integrative Allergy and Immunology Care, Charlotte, NC.

The results should be considered in the context of the study’s limitations, including the evaluation of three manufacturing lots and the relatively limited postmarketing surveillance period. Spontaneous adverse-event reporting systems are also subject to underreporting and cannot establish the absence of risk or a causal relationship between a manufacturing process and clinical outcomes. Thrombosis remains a labeled risk for all IVIG products, including ASCENIV™ and BIVIGAM®.

The peer-reviewed article is available through Frontiers in Cardiovascular Medicine at: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2026.1874074/full.

About ASCENIV™

ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). ASCENIV was approved by the United States Food and Drug Administration (FDA) in April 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), also known as primary immune deficiency disease (PIDD), in adults and pediatric patients (2 years of age and older). ASCENIV is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and respiratory syncytial virus (RSV) plasma obtained from donors tested using the Company’s proprietary microneutralization assay. ASCENIV contains naturally occurring polyclonal antibodies, which are proteins that are used by the body’s immune system to neutralize microbes such as bacteria and viruses that safeguard against infection and disease. ASCENIV is protected by numerous issued patents in the United States and internationally and a wide range of patent applications worldwide. Certain data and other information about ASCENIV can be found by visiting www.asceniv.com. Information about ADMA and its products can be found on the Company’s website at www.admabiologics.com.

Important Safety Information About ASCENIV™

| | WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE | |

| | | |

| | Thrombosis may occur with immune globulin intravenous (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Such events require immediate medical intervention, if not recognized or managed appropriately, may result in persistent or significant disability or lead to fatal outcome. For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. | |

| | | |

ASCENIV™ Contraindications:

History of anaphylactic or severe systemic reactions to human immunoglobulin.

IgA deficient patients with antibodies to IgA and a history of hypersensitivity.

ASCENIV™ Warnings and Precautions:

IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have medications such as epinephrine available to treat any acute severe hypersensitivity reactions. [4, 5.1]

Thrombotic events have occurred in patients receiving IGIV treatments. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for patients at risk of hyperviscosity. [5.2, 5.4]

In patients at risk of developing acute renal failure, monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output. [5.3, 5.9]

Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV treatment. [5.4]

Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. [5.5]

Hemolytic anemia can develop subsequent to IGIV treatment. Monitor patients for hemolysis and hemolytic anemia. [5.6]

Monitor patients for pulmonary adverse reactions (Transfusion-related acute lung injury [TRALI]). If transfusion-related acute lung injury is suspected, test the product and patient for antineutrophil antibodies. [5.7]

Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. [5.8]

ASCENIV™ Adverse Reactions:

The most common adverse reactions to ASCENIV (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea.

To report SUSPECTED ADVERSE REACTIONS, contact ADMA Biologics at (800) 458-4244 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About BIVIGAM®

BIVIGAM (immune globulin intravenous, human – 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). BIVIGAM was approved by the FDA in May 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients (2 years of age and older), including, but not limited to the following group of genetic disorders: X-linked and congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency. BIVIGAM contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses and help to protect PI patients against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin antibodies. Certain data and other information about BIVIGAM® or ADMA Biologics and its products can be found on the Company’s website at www.admabiologics.com.

Important Safety Information About BIVIGAM®

| | WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE | |

| | | |

| | **Thrombosis may occur with immune globulin intravenous (IGIV) products, including BIVIGAM. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, a history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors.****Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of Immune Globulin Intravenous (Human) (IGIV) products in predisposed patients.****Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. BIVIGAM does not contain sucrose.**For patients at risk of thrombosis, renal dysfunction or renal failure, administer BIVIGAM at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. | |

| | | |

BIVIGAM® Contraindications:

History of anaphylactic or severe systemic reactions to human immunoglobulin.

IgA deficient patients with antibodies to IgA and a history of hypersensitivity.

BIVIGAM® Warnings and Precautions:

Thrombotic events have occurred in patients receiving IGIV therapy. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for those at risk of hyperviscosity. [5.1, 5.4]

IgA deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have medications such as epinephrine available immediately to treat any acute severe hypersensitivity reactions. [4, 5.2]

Monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output in patients at risk of developing acute renal failure. [5.3, 5.9]

Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV therapy. [5.4]

Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. [5.5]

Hemolytic anemia can develop subsequent to treatment with IGIV products. Monitor patients for hemolysis and hemolytic anemia. [5.6]

Monitor patients for pulmonary adverse reactions (Transfusion-related acute lung injury [TRALI]). If transfusion-related acute lung injury is suspected, test the product and patient for antineutrophil antibodies. [5.7]

Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. [5.8]

BIVIGAM® Adverse Reactions:

The most common adverse reactions to BIVIGAM (reported in ≥5% of clinical study subjects) were headache, fatigue, infusion site reaction, nausea, sinusitis, blood pressure increased, diarrhea, dizziness, and lethargy.

To report SUSPECTED ADVERSE REACTIONS, contact ADMA Biologics at (800) 458-4244 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three FDA-approved plasma-derived biologics: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products and product candidates. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons.

ADMA holds numerous U.S. and foreign patents encompassing various aspects of its products, manufacturing processes and product candidates. For more information, please visit www.admabiologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 about ADMA Biologics, Inc. (“ADMA” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “position us,” “positioned,” “support,” “should,” “could,” “would,” “may,” “potential,” “view,” “opportunity” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, without limitation, statements concerning the potential implications of the published analytical and postmarketing findings; the capabilities and potential benefits of ADMA’s manufacturing process; the quality and differentiation of ADMA’s IVIG portfolio; and the Company’s continued manufacturing, development and commercialization activities.

Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there can be no assurance that the forward-looking statements included in this press release will prove accurate. Except as required by applicable laws or regulations, ADMA undertakes no obligation to update any forward-looking statement or announce revisions to any forward-looking statement. Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of events to differ materially from any future results expressed or implied by the forward-looking statements, including the risks and uncertainties described in ADMA’s filings with the U.S. Securities and Exchange Commission, including its most recent reports on Forms 10-K, 10-Q and 8-K and any amendments thereto.

INVESTOR RELATIONS CONTACT: Argot Partners | 212-600-1902 | [email protected]

MEDIA CONTACT: Longacre Square Partners | [email protected]

Prompts

ADMA Biologics Inc (ticker ADMA), listed in United States.

Company History

Date Change Detail
Feb 22, 2012 Renamed R&R ACQUISITION VI, INC → ADMA BIOLOGICS, INC.

ETFs Holding ADMA Biologics Inc

ETF Weight in ETF Shares Market value As of
TMFS 1.45% 89,662 $ 841.926K Aug 31, 2026
FFOX 0.87% 248,524 $ 2.08M Jun 30, 2026
IVSS 0.33% 10,720 $ 89.726K Jun 30, 2026
SYZ 0.17% 13,823 $ 115.699K Jun 30, 2026
FSCC 0.16% 61,458 $ 577.091K Aug 31, 2026
RUSC 0.14% 13,521 $ 113.171K Jun 30, 2026
FSEG 0.13% 904 $ 7,566.48 Jun 30, 2026
AVSC 0.10% 226,745 $ 3.054M Nov 16, 2026
PSC 0.09% 244,006 $ 2.042M Jun 30, 2026
RESM 0.06% 263 $ 2,201.31 Jun 30, 2026
DFAS 0.06% 1,486,934 $ 19.687M Nov 12, 2026
FSML 0.06% 8,271 $ 69.228K Jun 30, 2026
FESM 0.05% 333,822 $ 2.794M Jun 30, 2026
AVUQ 0.03% 8,366 $ 112.69K Nov 16, 2026
SMDX 0.02% 1,875 $ 25.256K Nov 17, 2026
VFQY 0.02% 10,305 $ 96.764K Aug 31, 2026
DXUV 0.01% 48,781 $ 645.86K Nov 12, 2026
AVUV 0.01% 166,836 $ 2.247M Nov 16, 2026
AVIE 0.01% 182 $ 2,451.54 Nov 16, 2026
MSSM 0.01% 4,841 $ 45.457K Aug 31, 2026
DCOR 0.01% 186,697 $ 2.472M Nov 12, 2026
DFUS 0.00% 41,956 $ 555.497K Nov 12, 2026
DFAU 0.00% 24,505 $ 324.446K Nov 12, 2026
DFAC 0.00% 150,689 $ 1.995M Nov 12, 2026
AVUS 0.00% 21,216 $ 285.78K Nov 16, 2026
NTRL 0.00% 11,074 $ 0.00 Nov 16, 2026